Microdosing mescaline means repeatedly taking small, non-hallucinogenic amounts of a cactus-derived psychedelic, hoping for better mood, focus, sleep and brain health. Little evidence concerns mescaline microdoses; controlled studies of other psychedelics found few lasting benefits beyond expectation, a reading some consider premature. Open questions include unpredictable cactus strength, breaks from reality in vulnerable people, dangerous combinations with lithium and some antidepressants, and an unproven long-term heart-valve risk. Benefits remain unestablished. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Blood pressure (seated) | <120/80 mmHg | Detects blood pressure rise |
| Resting heart rate | 50–70 beats/min | Detects stimulant effect |
| eGFR | >90 mL/min/1.73 m² | Kidney clearance of mescaline |
| ALT | <25 U/L | Screens liver health on co-medications |
| PHQ-9 score | 0–4 | Tracks depressive symptoms |
| GAD-7 score | 0–4 | Tracks anxiety |
| Echocardiogram | No more than trace valve regurgitation; no leaflet thickening | Detects valve changes |
| Sleep duration (wearable) | 7–9 hours, within 30 minutes of own baseline | Detects sleep disruption |
Cadence: Baseline before the first dose; blood pressure 2 hours after each of the first three doses; questionnaires at 2, 4 and 8 weeks of each course; kidney and liver tests every 6–12 months; echocardiogram every 12 months once cumulative use exceeds 6 months